A. J. Garber

The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man.

A. J. Garber, Philip E. Cryer, Julio V. Santiago et al. · Journal of Clinical Investigation · 1976 · 354 citations · Full text

Life Sciences, Endocrinology, Hormone Biochemistry +16

Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

Johan Jendle, Michael A. Nauck, David R. Matthews et al. · Diabetes Obesity and Metabolism · 2009 · 304 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study*

A. J. Garber, Anja Schweizer, Michelle A. Baron et al. · Diabetes Obesity and Metabolism · 2006 · 269 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study)

A. J. Garber, Jack Wahlen, Tyler S. Wahl et al. · Diabetes Obesity and Metabolism · 2005 · 261 citations · Full text

Medicine, Endocrinology, Pharmacology +17

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

Richard E. Pratley, Michael A. Nauck, Timothy S. Bailey et al. · International Journal of Clinical Practice · 2011 · 249 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17